Sequana Medical, a company targeting fluid overload in liver disease, heart failure and cancer, has enrolled the first patient in its MOJAVE study. MOJAVE, a randomised controlled Phase I/IIa study in the US, will evaluate the safety and efficacy of the company’s second-generation DSR product (DSR 2.0) in diuretic-resistant chronic heart failure patients with persistent […]